Results 211 to 220 of about 56,778 (348)
Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors [PDF]
Anastasia Shakhbazova +2 more
openalex +1 more source
ABSTRACT Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, life‐threatening mucocutaneous reactions. Pediatric mortality is lower than in adults, but children face higher risks of recurrence and long‐term sequelae. Despite disease severity, pediatric‐specific guidelines remain scarce and often extrapolated from adult ...
Rachel Creighton +3 more
wiley +1 more source
Fixed Drug Eruptions Due To/Caused by Levocetirizine and Cetirizine: An Uncommon Adverse Cutaneous Drug Reaction to Commonly Used Piperazine Derivatives. [PDF]
Tyagi M +5 more
europepmc +1 more source
ABSTRACT Background Dermatologic conditions are a significant reason for pediatric hospitalizations in the United States. A prior analysis of the 2012 Kids' Inpatient Database (KID) established a national benchmark for this burden, but changes in medical coding, healthcare delivery, and demographics necessitate an updated assessment.
Shiv Patel +3 more
wiley +1 more source
Autoimmune sequelae in severe drug eruptions [PDF]
Aoyama Y +7 more
europepmc +1 more source
Progressive Linear Bullous Eruption in a Young Athlete: A Diagnostic Challenge
Journal of Paediatrics and Child Health, EarlyView.
Chon‐Wai Jeremy Chan +4 more
wiley +1 more source
Dermatologic Findings of RELA‐Associated Autoinflammatory Disease
ABSTRACT Variants in the gene RELA have been implicated in a monogenic, hereditary form of Behcet's‐like syndrome. This case series describes the dermatologic manifestations of three patients with identified RELA‐associated autoinflammatory disease.
Elizabeth Nourse +4 more
wiley +1 more source
A case of drug‐induced Stevens‐Johnson syndrome‐like eruption predominating in mucosa: A case report
Akihiro Ishiguro +6 more
openalex +1 more source
Setmelanotide in Bardet‐Biedl Syndrome: A Case Report
ABSTRACT Setmelanotide is a melanocortin‐4‐receptor agonist used for the treatment of hyperphagia in the genetic obesity syndrome Bardet‐Biedl. Presented is a case of diffuse hyperpigmentation in a patient treated with setmelanotide, which represents the most common side effect of this medication.
Shelby Smith +2 more
wiley +1 more source

